Vor Biopharma Inc. (VOR)
NASDAQ: VOR · Real-Time Price · USD
18.33
+0.02 (0.11%)
Sep 29, 2026, 4:00 PM EDT - Market closed
Vor Biopharma Employees
Vor Biopharma had 76 employees as of December 31, 2025. The number of employees decreased by 83 or -52.20% compared to the previous year.
Employees
76
Change
-83
Growth
-52.20%
Revenue / Employee
n/a
Profits / Employee
$8,260,289
Market Cap
1.08B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 76 | -83 | -52.20% |
| Sep 30, 2025 | 154 | -5 | -3.14% |
| Jun 30, 2025 | 154 | - | - |
| Dec 31, 2024 | 159 | -9 | -5.36% |
| Dec 31, 2023 | 168 | 35 | 26.32% |
| Dec 31, 2022 | 133 | -2 | -1.48% |
| Dec 31, 2021 | 135 | 47 | 53.41% |
| Sep 30, 2021 | 122 | 52 | 74.29% |
| Jun 30, 2021 | 109 | 39 | 55.71% |
| Mar 31, 2021 | 92 | 22 | 31.43% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Immatics | 704 |
| MannKind | 592 |
| Replimune Group | 465 |
| MeiraGTx Holdings | 393 |
| Monte Rosa Therapeutics | 173 |
| MoonLake Immunotherapeutics | 130 |
| Adlai Nortye Group | 109 |
| Alto Neuroscience | 68 |
VOR News
- 14 hours ago - Vor Bio announces new post hoc analysis from Phase 3 trial on telitacicept - TheFly
- 14 hours ago - Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis - GlobeNewsWire
- 6 days ago - Vor Biopharma Transcript: Stifel 2026 Virtual Immunology and Inflammation Forum - Transcripts
- 20 days ago - Vor Biopharma Transcript: Citigroup’s Biopharma Back to School Summit 2026 - Transcripts
- 21 days ago - Vor Biopharma Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 21 days ago - Vor Bio completes enrollment in UPSTREAM MG trial - TheFly
- 21 days ago - Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis - GlobeNewsWire
- 23 days ago - Vor Biopharma Slides: Corporate presentation - Filings